1 Rewa O, Villeneuve PM, Eurich DT, et al. Quality indicators in continuous renal replacement therapy (CRRT) care in critically ill patients: protocol for a systematic review. Syst Rev. 2015;4:102.
2 Elseviers MM, Lins RL, Van der Niepen P, et al. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury. Crit Care. 2010;14:R221.
3 Vinsonneau C, Allain‑Launay E, Blayau C, et al. Épuration extrarénale en réanimation adulte et pédiatrique: Recommandations formalisées de la Société de réanimation de langue française (SRLF) et de la Société française d’anesthésie-réanimation (Sfar). Revue Réanimation Novembre. 2014;23(6):714–37.
4 Vanholder R, Canaud B, Fluck R, et al. Diagnosis, prevention, and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2010;3:234–46.
5 Moran JE, Ash SR, ASDIN Clinical Practice Committee. Locking solutions for hemodialysis catheters; heparin and citrate: a position paper by ASDIN. Semin Dial. 2008;21(5):490–2.
6 Correa Barcellos F, Pereira Nunes B, Jorge Valle L, et al. Comparative effectiveness of 30% trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial). Infection. 2016;4:441–564.
7 Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al. Randomized clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16(9):2769–77.
8 Bruyère R, Soudry-Faure A, Capellier G, et al. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial. Trials. 2014;15:449.
9 De Broucker M, Décaudin B, Dewulf S, et al. Incompatibilité physico-chimique entre polyéthylène glycol et cathéters centraux d’hémodialyse en polyuréthane. J Pharm Clin. 2007;26(2):119–22.
10 Mimoz O, Lucet JC, Kerforne T, et al. Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet. 2015;386(10008):2069–77.
11 Ronco C, Homel P, Bellomo R, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30.
12 Uchino S, Fealy N, Baldwin I, et al. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract. 2003;94:94–8.
13 Van der Voort PH, Gerritsen RT, Kuiper MA, et al. Filter run time in CVVH: pre-versus postdilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif. 2005;23:175–80.
14 Nurmohamed SA, Jallah BP, Vervloet MG, et al. Predilution versus postdilution continuous venovenous hemofiltration: no effect on filter life and azotemic control in critically ill patients on heparin. ASAIO J. 2011;57(1):48–52.
15 Klingel R, Schaefer M, Schwarting A, et al. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation. Nephrol Dial Transplant, 2004;19:164–70.
16 Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant. 2006;21:444–9.
17 Monti G, Herrera M, Kindgen-Milles D, et al. The DOse REsponse Multicentre International Collaborative Initiative (DO-RE-MI). Contrib Nephrol. 2007;156:434–43.